CANCER THERAPY

POWERED BY YOU

Syncromune® is at the forefront of developing new immunotherapies  designed to empower the immune system to fight cancer

®

PATIENT RESOURCES

The following are additional resources to learn more about immunotherapy, SYNC-T's initial indications, metastatic non-small cell lung cancer, metastatic breast cancer, and metastatic castrate-resistant prostate cancer

  • CURRENT SYNC-T™ TRIALS
  • AMERICAN LUNG ASSOCIATION
  • NATIONAL CANCER INSTITUTE
  • AMERICAN CANCER SOCIETY
  • CANCER.NET
  • CURRENT SYNC-T™ TRIALS
  • AMERICAN CANCER SOCIETY
  • CDC
  • CANCER CARE
  • BREAST CANCER RESEARCH FOUNDATION
  • CURRENT SYNC-T™ TRIALS
  • PROSTATE CANCER FOUNDATION
  • NATIONAL CANCER INSTITUTE
  • CANCER CARE
  • ZERO CANCER

Investigational Clinical Trials for Solid Tumors

We’re committed to our mission of developing new therapies that may help improve the lives of patients with cancer. Our clinical trials for solid tumor cancers study combination investigational drugs and medical devices. Some of these trials are investigator-initiated by external researchers to assess the potential of these therapies in treating advanced cancer. We collaborate with these investigators to contribute to the advancement of cancer treatment.

STATUS

TRIAL NAME

TRIAL REFERENCE NUMBER

ENROLLMENT CLOSED

Phase 1 Investigator Initiated Trial of SYNC-T SV-102 Immunotherapy for Advanced/​Metastatic Castrate-Resistant Prostate Cancer

Locations

Hospital Diomed
Mexico City, MX

Condition

Metastatic Castrate-Resistant Prostate Cancer

STATUS

TRIAL NAME

TRIAL REFERENCE NUMBER

RECRUITING

Phase 1 Investigator Initiated Trial of SYNC-T SV-101 Immunotherapy for Patients With Advanced / Metastatic Breast Cancer

Locations

Hospital Diomed
Mexico City, MX

Condition

Metastatic Breast Cancer

STATUS

TRIAL NAME

TRIAL REFERENCE NUMBER

RECRUITING

Phase 1 Investigator Initiated Trial of SYNC-T SV-101 Immunotherapy for Patients With Advanced / Metastatic Non-Small Cell Lung Cancer

Locations

Hospital Diomed
Mexico City, MX

Condition

Non-Small Cell Lung Cancer

STATUS

TRIAL NAME

TRIAL REFERENCE NUMBER

NOT YET RECRUITING

A Phase 1b, Open-label, Two-part, Dose-escalation and Expansion Study of SV-102 in Combination with Cryolysis in Patients with Advanced/Metastatic Castration-resistant Prostate Cancer or those with Metastatic Prostate Cancer who Refuse(d) Hormone Therapy and Chemotherapy

N/A

Locations

United States

Condition

Metastatic Castrate-Resistant Prostate Cancer

STATUS

TRIAL NAME

TRIAL REFERENCE NUMBER

NOT YET RECRUITING

A Phase 1b, Open-label, Two-part, Dose-escalation and Expansion Study of SV-101 in Combination with Cryolysis in Patients with Advanced/Metastatic Breast Cancer, Non-Small Cell Lung Cancer, or Solid Tumor Cancer

N/A

Locations

United States

Condition

Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic Solid Tumor Cancers

Expanded Access to Investigational Therapies

Syncromune is an oncology-focused biopharmaceutical company committed to developing therapies that may improve the lives of cancer patients. Our focus centers around conducting clinical research that evaluates the safety and effectiveness of new therapies for patients with solid tumor cancers. Our clinical trial programs are the primary way to get access to a Syncromune investigational therapy. These clinical trials provide the most effective way to assess how our investigational therapies may treat cancer, and are used to support regulatory approval.

At this time,  Syncromune does not provide access to investigational therapies outside of clinical trials or prior to regulatory approval. You and your health care provider may learn more about our clinical trials by going to the clinical trials section of our website, or visiting ClinicalTrials.gov and searching for Syncromune.

If you are a health care provider who is interested in learning more about one of our investigational therapies, or a physician with questions about participation in one of our clinical trials, please submit a request to trials@syncromune.com.  Syncromune will acknowledge your request as soon as possible, typically within 3 days of receipt.

If applicable, this website will be updated with hyperlinks to the relevant expanded access information on ClinicalTrials.gov . Syncromune reserves the right to revise this expanded access policy at any time.

Pursuant to the 21st Century Cures Act, the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual.

Disclaimers: The content on this website is intended for healthcare professionals. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the relevant regulatory authorities, including the US Food and Drug Administration or other applicable agencies in other countries.

2919 E. Commercial Blvd.
Fort Lauderdale, FL 33308